PACIRA BIOSCIENCES, INC. Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred
PACIRA BIOSCIENCES, INC. (PCRX) reported Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred of $0 for the 13-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred · last filed 2023-02-28
- 2022-12-31: Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred 13 month $0.00.
- 2022-09-30: Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred 10 month $0.00.
- 2022-06-30: Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred 7 month $0.00.
- 2022-03-31: Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred 4 month $0.00.
| Period end | Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred 4 month | Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred 7 month | Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred 10 month | Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred 13 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-03 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |